Form 4: ResMed CEO Michael Farrell Trades Shares Under 10b5-1 Plan

ResMed Inc. Chairman and CEO Michael Farrell reported transactions involving company stock, including acquisitions and dispositions, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael J. Farrell, Chairman and CEO of ResMed Inc., engaged in stock transactions on May 7, 2026.
• He acquired 4,991 shares of ResMed Common Stock at an average price of $146.34 per share.
• Concurrently, he disposed of 4,991 shares of ResMed Common Stock at a weighted average sale price of $207.82.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024.
• Following these transactions, Farrell directly beneficially owns 466,223 shares of ResMed Common Stock.
• An additional 2,090 shares are held indirectly through the Lisette and Michael Farrell Family Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the CEO sold a significant number of shares, the execution under a Rule 10b5-1 plan mitigates concerns about opportunistic insider trading. The acquisition and disposition on the same day under a plan is unusual but not inherently negative without further context.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider trading activity.
• The CEO continues to hold a significant number of shares (466,223 directly, 2,090 indirectly), demonstrating continued investment in the company.

Negatives

• The disposal of 4,991 shares at a higher price than the acquisition price represents a significant sale of stock by the CEO.

Risks

• While executed under a 10b5-1 plan, significant stock sales by a CEO can sometimes be perceived negatively by the market, potentially impacting investor sentiment.
• The price difference between acquisition and disposition ($146.34 vs. $207.82) suggests a substantial gain realized by the CEO, but the reason for acquiring at a lower price and selling at a higher price within the same day under a plan is not detailed.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions.

Management Comments

• The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
• This transaction was executed in multiple trades at prices ranging from $206.45 - $210.47. The price reported above reflects the weighted average sale price.
• Represents date options first become exercisable. Options vest 1/3 per year.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by ResMed's CEO is a common strategy to diversify or monetize holdings while mitigating concerns about insider trading, especially in the healthcare technology sector where predictable revenue streams are valued.

Stakeholder Impact

• Shareholders: May observe the CEO's stock sale, potentially influencing short-term trading sentiment, though the 10b5-1 plan provides a degree of reassurance.
• Employees: The CEO's continued direct and indirect ownership suggests confidence in the company's long-term prospects.
• Creditors: Unlikely to be directly impacted by this specific insider transaction.

Next Steps

• Continued monitoring of ResMed's stock performance and any further insider transactions.
• Review of future quarterly and annual reports for overall company financial health and strategic updates.

Key Dates

Recommendation

The filing reports routine insider transactions under a pre-established plan, which is standard practice and generally not indicative of a significant shift in the company's fundamental value. While the CEO sold shares, the acquisition and sale on the same day under a 10b5-1 plan is unusual but doesn't provide enough information to warrant a strong buy or sell recommendation. A 'hold' reflects the neutral nature of this disclosure.

Keywords

ResMed, RMD, Form 4, Insider Trading, Rule 10b5-1, Stock Transaction, CEO, Michael Farrell, Beneficial Ownership, Securities Exchange Act